Clinical trial
The Value of Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
Name
SHLTQC-5
Description
To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.
Trial arms
Trial start
2013-01-01
Estimated PCD
2023-12-31
Trial end
2024-01-01
Status
Completed
Treatment
PVHA or TACE
PVHA or TACE
Arms:
PVHA, TACE
Size
197
Primary endpoint
Underwent LT
January 2013 and December 2020
Successful downstaging
January 2013 and December 2020
Eligibility criteria
(1) age ≥18 years; (2) exceeding UCSF criteria; (3) absence of vascular invasion, nodal involvement, or extrahepatic metastases; (4) receiving TACE treatment or LTFVD treatment for downstaging purposes.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 197, 'type': 'ACTUAL'}}
Updated at
2024-01-09
1 organization
1 product
1 indication
Product
PVHAIndication
Liver Transplant